Oct 08, 2025 8:05am EDT Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Aug 05, 2025 4:01pm EDT Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 29, 2025 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
May 22, 2025 5:20pm EDT Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
May 06, 2025 4:01pm EDT Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 29, 2025 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Mar 27, 2025 8:05am EDT Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
